[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558161":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":36,"locations":43,"responsibleParty":63,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":10,"enrollmentInfo":78,"targetDuration":81,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"CHU de Quebec-Universite Laval","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Sleeve gastrectomy - Men",null,"n = 39 men with obesity undergoing sleeve gastrectomy",[13],"Procedure: Bariatric surgery",{"label":15,"type":10,"description":16,"interventionNames":17},"Sleeve gastrectomy - Premenopausal women","n = 39 premenopausal women with obesity undergoing sleeve gastrectomy",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Sleeve gastrectomy - Postmenopausal women","n = 39 postmenopausal women with obesity undergoing sleeve gastrectomy",[13],{"label":23,"type":10,"description":24,"interventionNames":10},"Obese non-surgical group","n = 39 (13 men, 13 premenopausal and 13 postmenopausal women) obese non-surgical individuals",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"PROCEDURE","Bariatric surgery","Sleeve gastrectomy",[9,19,15],[32],{"name":33,"affiliation":34,"role":35},"Claudia Gagnon, Dr","CHU de Québec - Université Laval","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Sandrine Hegg-Deloye, PhD","CONTACT","4185254444","48729","sandrine.hegg-deloye@crchudequebec.ulaval.ca",[44],{"facility":45,"status":46,"city":47,"state":10,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Centre de recherche de l'IUCPQ","RECRUITING","Québec","G1V 4G5","Canada","CA",{"type":52,"coordinates":53},"Point",[54,55],-71.21454,46.81228,{"lat":55,"lon":54},[58,62],{"name":59,"role":39,"phone":60,"phoneExt":41,"email":61},"Sandrine Hegg-Deloye","418-525-4444","sandrine-hegg-deloye@crchudequebec.ulaval.ca",{"name":33,"role":35,"phone":10,"phoneExt":10,"email":10},{"type":35,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Claudia Gagnon","Principal Investigator, Endocrinologist, Regular Researcher of the Endocrinology-Nephrology Axis",[67],{"name":68,"class":6},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","100558161","bone-and-muscle-health-following-sleeve-gastrectomy-in-men-premenopausal-and-postmenopausal-women-100558161",false,"NCT06547515","Bone and Muscle Health Following Sleeve Gastrectomy in Men, Premenopausal and Postmenopausal Women","BONUS","Inclusion Criteria:\n\n* Men and women aged \\>18 years;\n* Awaiting SG for the bariatric group or meeting the criteria for SG but not undergoing surgery for the non-surgical group.\n* Menopause: defined as the absence of menses for a year and a serum follicular-stimulating hormone (FSH) \\>40 UI\u002FL.\n* Women taking oral contraceptive pills or hormone replacement therapy\n* Patients with type 2 diabetes.\n\nExclusion Criteria:\n\n* Type 1 diabetes;\n* Disease (e.g., uncontrolled thyroid disease, Malabsorptive or overt inflammatory disorder)\n* Metabolic bone disease other than osteoporosis or type 2 diabetes,\n* Creatinine clearance \\\u003C30 ml\u002Fmin) or medication (e.g., glucocorticoids, anti-epileptic drugs, osteoporosis therapy, thiazolidinediones) affecting bone metabolism;\n* Weight \\>204 kg (DXA weight limit) or BMI \\>60 kg\u002Fm2 (upper limit to allow for QCT examination);\n* Current or planned pregnancy during follow-up; breast-feeding.","ALL","18 Years",{"count":79,"type":80},156,"ESTIMATED","36 Months","OBSERVATIONAL","Background: Bariatric surgery is gaining in popularity. While it's health benefits are undisputed, the older malabsorptive bariatric procedures (Roux-in-Y gastric bypass - RYGB and biliopancreatic diversion - BPD) are associated with an increased risk of fractures and falls as early as 3-5 years after surgery. Sleeve gastrectomy - SG is now the most performed bariatric procedure. Although SG does not cause malabsorption, it is predicted to result in bone and muscle loss via weight loss and weight loss-independent mechanisms. Primary aim: to compare the changes in spine volumetric bone mineral density (vBMD) by quantitative computed tomography (QCT) and muscle mass at mid-femur by computed tomography (CT) at 3 years in the 3 groups of: 1) men; 2) premenopausal women; 3) postmenopausal women after SG versus their respective non-surgical peers who did not undergo SG in the 3-year period following recruitment. Secondary aims: to compare the changes in vBMD by QCT at skeletal sites other than the spine and in areal bone mineral density (aBMD) by dual-energy X-ray absorptiometry (DXA), whole-body muscle mass by DXA, muscle quality by CT at mid-femur and muscle strength as well as in selected physical performance and capacity tests shown to predict falls and fractures between 0-1 and 1-3 years after SG in the same 3 groups after SG vs. in the respective non-surgical groups.",[85,86,87,88],"Bariatric Surgery","Bone Health","Severe Obesity","Muscle Health",[90,91,87,88],"bariatric surgery","Bone health","2025-06-05",{"date":94,"type":95},"2025-06-10","ACTUAL",{"date":97,"type":95},"2022-09-14",{"date":99,"type":80},"2026-08-15",{"name":5,"class":6},1]